Remission of disseminated cancer after systemic oncolytic virotherapy

Stephen J. Russell; Mark J. Federspiel; Kah Whye Peng; Caili Tong; David Dingli; William G. Morice; Val Lowe; Michael K. O'Connor; Robert A. Kyle; Nelson Leung; Francis K. Buadi; S. Vincent Rajkumar; Morie A. Gertz; Martha Q. Lacy; Angela Dispenzieri

doi:10.1016/j.mayocp.2014.04.003

Remission of disseminated cancer after systemic oncolytic virotherapy

Stephen J. Russell, Mark J. Federspiel, Kah Whye Peng, Caili Tong, David Dingli, William G. Morice, Val Lowe, Michael K. O'Connor, Robert A. Kyle, Nelson Leung, Francis K. Buadi, S. Vincent Rajkumar, Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri

Research output: Contribution to journal › Article › peer-review

181 Scopus citations

Abstract

MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple glucose-avid plasmacytomas were treated by intravenous infusion of 10¹¹ TCID₅₀ (50% tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy with M protein reduction and resolution of bone-marrow plasmacytosis. Further, one patient experienced durable complete remission at all disease sites. Tumor targeting was clearly documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas. Toxicities resolved with in the first week after therapy. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated cancer.

Original language	English (US)
Pages (from-to)	926-933
Number of pages	8
Journal	Mayo Clinic proceedings
Volume	89
Issue number	7
DOIs	https://doi.org/10.1016/j.mayocp.2014.04.003
State	Published - Jul 2014

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/j.mayocp.2014.04.003

Cite this

Russell, S. J., Federspiel, M. J., Peng, K. W., Tong, C., Dingli, D., Morice, W. G., Lowe, V., O'Connor, M. K., Kyle, R. A., Leung, N., Buadi, F. K., Rajkumar, S. V., Gertz, M. A., Lacy, M. Q., & Dispenzieri, A. (2014). Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clinic proceedings, 89(7), 926-933. https://doi.org/10.1016/j.mayocp.2014.04.003

@article{7a70b70df03349e0829053239ef355f9,

title = "Remission of disseminated cancer after systemic oncolytic virotherapy",

abstract = "MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple glucose-avid plasmacytomas were treated by intravenous infusion of 1011 TCID50 (50% tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy with M protein reduction and resolution of bone-marrow plasmacytosis. Further, one patient experienced durable complete remission at all disease sites. Tumor targeting was clearly documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas. Toxicities resolved with in the first week after therapy. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated cancer.",

author = "Russell, {Stephen J.} and Federspiel, {Mark J.} and Peng, {Kah Whye} and Caili Tong and David Dingli and Morice, {William G.} and Val Lowe and O'Connor, {Michael K.} and Kyle, {Robert A.} and Nelson Leung and Buadi, {Francis K.} and Rajkumar, {S. Vincent} and Gertz, {Morie A.} and Lacy, {Martha Q.} and Angela Dispenzieri",

year = "2014",

month = jul,

doi = "10.1016/j.mayocp.2014.04.003",

language = "English (US)",

volume = "89",

pages = "926--933",

journal = "Mayo Clinic proceedings",

issn = "0025-6196",

publisher = "Elsevier Science",

number = "7",

}

TY - JOUR

T1 - Remission of disseminated cancer after systemic oncolytic virotherapy

AU - Russell, Stephen J.

AU - Federspiel, Mark J.

AU - Peng, Kah Whye

AU - Tong, Caili

AU - Dingli, David

AU - Morice, William G.

AU - Lowe, Val

AU - O'Connor, Michael K.

AU - Kyle, Robert A.

AU - Leung, Nelson

AU - Buadi, Francis K.

AU - Rajkumar, S. Vincent

AU - Gertz, Morie A.

AU - Lacy, Martha Q.

AU - Dispenzieri, Angela

PY - 2014/7

Y1 - 2014/7

N2 - MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple glucose-avid plasmacytomas were treated by intravenous infusion of 1011 TCID50 (50% tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy with M protein reduction and resolution of bone-marrow plasmacytosis. Further, one patient experienced durable complete remission at all disease sites. Tumor targeting was clearly documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas. Toxicities resolved with in the first week after therapy. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated cancer.

AB - MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple glucose-avid plasmacytomas were treated by intravenous infusion of 1011 TCID50 (50% tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy with M protein reduction and resolution of bone-marrow plasmacytosis. Further, one patient experienced durable complete remission at all disease sites. Tumor targeting was clearly documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas. Toxicities resolved with in the first week after therapy. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated cancer.

UR - http://www.scopus.com/inward/record.url?scp=84904744363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904744363&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2014.04.003

DO - 10.1016/j.mayocp.2014.04.003

M3 - Article

C2 - 24835528

AN - SCOPUS:84904744363

SN - 0025-6196

VL - 89

SP - 926

EP - 933

JO - Mayo Clinic proceedings

JF - Mayo Clinic proceedings

IS - 7

ER -

Remission of disseminated cancer after systemic oncolytic virotherapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this